Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited has announced a proposed capital raising through an accelerated non-renounceable entitlement offer and a separate placement of ordinary fully paid shares, together amounting to a potential issue of 435,445,335 new shares. The accelerated offer, which includes institutional and retail components, and the additional placement are structured to raise new equity capital, with defined ex-entitlement, record, closing, and issue dates, and are expected to strengthen the company’s balance sheet and provide funding flexibility for its ongoing operations and strategic initiatives, potentially affecting existing shareholders through dilution but improving the company’s financial capacity.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX, focused on developing therapeutic products, with its primary securities being ordinary fully paid shares traded under the code PYC.
Average Trading Volume: 477,141
Technical Sentiment Signal: Buy
Current Market Cap: A$933.2M
See more insights into PYC stock on TipRanks’ Stock Analysis page.